Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.49 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12426288 | 0.84 | MKNK2 (0.39) | TGFBR1CYP2A6IDO1 | |
| SCHEMBL12426538 | 0.80 | ELANE (0.39) | TGFBR1TGFBR2CYP2A6IDO1 | |
| SCHEMBL12424837 | 0.77 | TGFBR1 (0.40) | TGFBR1TGFBR2CDC7CDK2IDO1 | |
| SCHEMBL12424675 | 0.76 | TGFBR1 (0.44) | TGFBR1TGFBR2CDC7CDK2IDO1 | |
| SCHEMBL12424762 | 0.74 | TGFBR1 (0.35) | TGFBR1TGFBR2CDC7CDK2MAPT | |
| SCHEMBL15976496 | 0.74 | TGFBR1 (0.35) | TGFBR1TGFBR2CDC7CDK2IDO1 | |
| SCHEMBL3393742 | 0.73 | CYP2A6 (0.40) | TGFBR1TGFBR2CYP2A6IDO1 | |
| SCHEMBL246878 | 0.72 | ADORA1 (0.48) | TGFBR1TGFBR2CYP2A6MAPT | |
| SCHEMBL14241409 | 0.72 | CCR1 (0.50) | TGFBR1TGFBR2CYP2A6 | |
| SCHEMBL246499 | 0.71 | TGFBR1 (0.43) | TGFBR1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539336-B1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | ATP5ME, ATP5F1A, ATP5F1D | TGFBR1 3742/4885TGFBR2 4037/4885CYP2A6 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.